Inogen Q1 2023 revenue $72.2M, net loss $20.3M; sees positive adjusted EBITDA by Q4 2023

Inogen Inc

2023-Q1 EPS reported -$0.88 revenue$72,162,000

Total revenue $72.2M, down 10.2% YoY; rental revenue up 25.4% YoY.
GAAP net loss $20.3M vs $14.2M loss in Q1 2022; adjusted net loss $14.5M vs $8.7M.
Adjusted EBITDA loss $11.8M vs $5.0M loss; expects positive adjusted EBITDA by Q4 2023.
Cash and marketable securities $174.6M; no debt outstanding.
Notified of France reimbursement for Rove 6; added two large private payers covering ~160M lives.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Inogen Inc reported the quarter ended March 31, 2023 results: revenue $72.2 million, net income GAAP net loss of $20.3 million.

Period: the quarter ended March 31, 2023
Revenue: $72.2 million
Net income: GAAP net loss of $20.3 million
Result: reported results

Exact text from the filing

Inogen Announces First Quarter 2023 Financial Results Total Revenue of $72.2 Million In Line with Company Expectations Rental Revenue Year-over-Year Growth of 25% GOLETA, Calif., May 04, 2023 -- Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Inogen Inc filing history →

Source: SEC EDGAR

accession 0000950170-23-017865

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.